These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2639762)

  • 1. Structural intermediates in the reactions of antigenic peptides with MHC molecules.
    Dornmair K; Rothenhäusler B; McConnell HM
    Cold Spring Harb Symp Quant Biol; 1989; 54 Pt 1():409-16. PubMed ID: 2639762
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the nature of physiologically processed antigen and on the conformation of peptides required for interaction with MHC.
    Grey HM; Demotz S; Buus S; Sette A
    Cold Spring Harb Symp Quant Biol; 1989; 54 Pt 1():393-9. PubMed ID: 2639761
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemistry of peptide interactions with MHC proteins.
    Sette A; Grey HM
    Curr Opin Immunol; 1992 Feb; 4(1):79-86. PubMed ID: 1596372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC products: biosynthesis, intracellular traffic, and "empty" molecules.
    Ploegh HL
    Cold Spring Harb Symp Quant Biol; 1992; 57():565-70. PubMed ID: 1339694
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigen-binding function of class II MHC molecules.
    Unanue ER; Harding CV; Luescher IF; Roof RW
    Cold Spring Harb Symp Quant Biol; 1989; 54 Pt 1():383-92. PubMed ID: 2639760
    [No Abstract]   [Full Text] [Related]  

  • 6. Stimulation of T cells by antigen-presenting cells is kinetically controlled by antigenic peptide binding to major histocompatibility complex class II molecules.
    McConnell HM; Wada HG; Arimilli S; Fok KS; Nag B
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2750-4. PubMed ID: 7708718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting peptide binding to Major Histocompatibility Complex molecules.
    Liao WW; Arthur JW
    Autoimmun Rev; 2011 Jun; 10(8):469-73. PubMed ID: 21333759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin.
    Zaghouani H; Kuzu Y; Kuzu H; Brumeanu TD; Swiggard WJ; Steinman RM; Bona CA
    Eur J Immunol; 1993 Nov; 23(11):2746-50. PubMed ID: 8223850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
    Adams S; Humphreys RE
    Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capture and processing of exogenous antigens for presentation on MHC molecules.
    Watts C
    Annu Rev Immunol; 1997; 15():821-50. PubMed ID: 9143708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.
    Afridi S; Hoessli DC; Hameed MW
    Immunol Rev; 2016 Jul; 272(1):151-68. PubMed ID: 27319349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules.
    Nelson CA; Vidavsky I; Viner NJ; Gross ML; Unanue ER
    Proc Natl Acad Sci U S A; 1997 Jan; 94(2):628-33. PubMed ID: 9012835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of antigenic peptide binding to the class II major histocompatibility molecule I-Ad.
    Tampé R; McConnell HM
    Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4661-5. PubMed ID: 2052549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding.
    Germain RN; Hendrix LR
    Nature; 1991 Sep; 353(6340):134-9. PubMed ID: 1891045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives: protein structure. Class-conscious TCR?
    Wilson IA
    Science; 1999 Dec; 286(5446):1867-8. PubMed ID: 10610577
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based design and evaluation of MHC class II binding peptides.
    de Haan EC; Wauben MH; Grosfeld-Stulemeyer MC; Moret EE
    Biologicals; 2001; 29(3-4):289-92. PubMed ID: 11851330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes.
    Peters PJ; Raposo G; Neefjes JJ; Oorschot V; Leijendekker RL; Geuze HJ; Ploegh HL
    J Exp Med; 1995 Aug; 182(2):325-34. PubMed ID: 7629497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-order reaction controls the binding of antigenic peptides to major histocompatibility complex class II molecules.
    Witt SN; McConnell HM
    Proc Natl Acad Sci U S A; 1991 Sep; 88(18):8164-8. PubMed ID: 1654561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of MHC-II binding affinity using particle swarm optimization.
    Zhang W; Liu J; Niu Y
    Artif Intell Med; 2010 Oct; 50(2):127-32. PubMed ID: 20541921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.